If buying of late is anything to go by, Ropren may be closer than we think. Once approved, the market for this drug in Russia alone is massive! Major hospitals have already expressed their desire to gain access to the drug as soon as it is approved. Obviously the demand in other countries will eventually be just as big, with the main target being liver disease, and neurological disorders such as Alzheimers and Dementia. A zero negative side effect drug of this kind has immense scope for use.
Also H. Pylori trial results expected soon. Alcoholic/drug addicts trial results also expected pending patent finalisation (these will be big news for sla, if anything bigger than previous trial results), and also waiting to hear who their strategic partner in Australia is for marketing Bio A in chemists, supermarkets and health stores. Bio A was launched here in Australian just over a week ago, revenue will start to flow in over the coming quarters.
Vagif is over in Europe and will be presenting at the European Gastroenterology Conference this month, where over 2000 medical experts from Europe will be attending.
Further Swinburn Trials to commence later this year.
Bio A, and Ropren and just two of the many drugs that this company will be marketing long term, but for now they are the main ones. Not to mention their agreement with BioProspect recently, opening the door to the animal nutrition, animal health and agriculture business.
Cheers Greg
SLA Price at posting:
0.0¢ Sentiment: ST Buy Disclosure: Held
